Characterization of two new point mutations in the low density lipoprotein receptor genes of an English patient with homozygous familial hypercholesterolemia

J. C. Webb, X-M. Sun, D. D. Patel, S. N. McCarthy, B. L. Knight, and A. K. Soutar

MRC Lipoprotein Team, Hammersmith Hospital, Ducane Road, London W12 OHS, England

Abstract Two new point mutations have been detected in the low density lipoprotein (LDL) receptor gene of a patient with a clinical diagnosis of homozygous familial hypercholesterolemia (FH). The patient is a compound heterozygote, in whom the mutant allele inherited from his English father has a single base substitution of A for G in exon 3, changing the codon for residue 80 in the mature protein from glutamic acid to lysine. The mutant allele inherited from his mother, who is of Irish origin, has a single base pair deletion in the codon for residue 743 in exon 15 that causes a frameshift and introduces a new stop codon in the adjacent position. The glu80 to lys mutation results in a transport-defective phenotype and a mature protein that migrates abnormally slowly on nonreduced SDS-PAGE, but normally under reducing conditions; this was confirmed by site-directed mutagenesis and expression in vitro. The deletion in exon 15 results in a null phenotype in which the putative truncated receptor protein cannot be detected in cultured skin fibroblasts and the amount of mRNA derived from the allele is reduced. The glu80 to lys mutation was found in a further five unrelated individuals in a sample of 200 FH patients from the London area and in 11 from a sample of 77 FH patients from Manchester. Haplotype analysis suggested that all the patients had inherited this allele from a common ancestor. The deletion in exon 15 was not found in the London sample, nor in any unrelated individuals in the Manchester sample.—Webb, J. C., X-M. Sun, D. D. Patel, S. N. McCarthy, B. L. Knight, and A. K. Soutar. Characterization of two new point mutations in the low density lipoprotein receptor genes of an English patient with homozygous familial hypercholesterolemia. J. Lipid Res. 1992. 33: 689-698.

Supplementary key words polymerase chain reaction • mismatch analysis • LDL receptor structure • population screening

Mutations in the gene for the low density lipoprotein (LDL) receptor cause the autosomal dominant inherited disease familial hypercholesterolemia (FH), which affects approximately one in 400 individuals in most populations. The LDL receptor is a cell-surface glycoprotein that mediates the specific uptake and catabolism of plasma LDL, and heterozygous FH individuals with one defective gene have a markedly raised plasma cholesterol that is frequently associated with the occurrence of tendon xanthomata, accelerated atherosclerosis, and premature coronary heart disease. Homozygous FH patients are more severely affected and, without intensive cholesterol-lowering treatment, rarely reach the age of maturity (1).

Much has already been learned about the relationship between structure and function of the different domains of the LDL receptor protein from studies of receptor function in cultured skin fibroblasts of FH patients with known mutations in the gene (2). A variety of different types of mutations have been characterized, including major gene rearrangements, small deletions, and point mutations, but with a few notable exceptions each of these has been observed in a single individual or family. The exceptions are cases where a founder gene in an isolated population has resulted in a higher than usual frequency of FH in which most of the patients have the same mutation. By contrast, in populations of very diverse ethnic origins, it has been estimated that more than 183 different mutant alleles of the LDL receptor gene may be responsible for FH (2). Nonetheless, while more restricted populations may not demonstrate the presence of a clear founder gene, a smaller number of mutations may be responsible for the disease in the majority of patients, so that a DNA-based diagnostic test would be feasible.

Identification of the specific mutation in the gene of an FH patient not only sheds further light on the way the LDL receptor functions in vivo, information that may also be relevant to other cell-surface receptor proteins, but will also allow comparisons to be made between groups of patients with either the same or different mutations in the gene. It has long been recognized that there is consider-
ble variation in the severity of the disease in FH patients, and in their response to cholesterol-lowering treatment, but the underlying genetic or environmental causes of the variation are poorly understood (1). In this report we describe the characterization of two new mutations in the LDL receptor gene of an FH homozygote patient of English origin. One of the mutations is very common in the English population, particularly in the north of England, while the other is uncommon, but probably originates from Ireland.

METHODS

Subjects

The proband is a boy of English origin who was given a clinical diagnosis of homozygous familial hypercholesterolemia at 1½ years of age, based on a markedly increased concentration of plasma cholesterol (30 mmol/l), the presence of tendon xanthomata, and a family history of premature coronary disease and hypercholesterolemia. There was no evidence for consanguinity in the family. The two samples of FH patients, 200 attending lipid clinics in the London area and 77 attending a lipid clinic in Manchester, have been described in detail elsewhere (3, 4).

Analysis of DNA

Genomic DNA was isolated as described previously (5) or by a rapid small scale method (4). Southern blotting was carried out by standard techniques (6) described in detail elsewhere (3). To detect major rearrangements in the LDL receptor gene, genomic DNA (10 µg) was digested either with PvuII or BglII and fractionated by agarose gel electrophoresis. After blotting, the PvuII-digested DNA was hybridized with a 1.9-kb BamHI fragment derived from the 3' end of the cDNA for the LDL receptor (plasmid pLDLR3, kindly supplied by Dr. D. Russell, Dallas, Texas). The BglII-digested DNA was hybridized with a 1.7-kb HndI/BglII probe derived from a 0.7-kb fragment encompassing exon 1 and the promoter region of the LDL receptor (plasmid pLDLR3, kindly supplied by Dr. D. Russell, Dallas, Texas). The BglII-digested DNA was hybridized with a 1.7-kb HndIII/BglII probe derived from the 5' end of cDNA, then stripped and re-probed with a 0.7-kb fragment encompassing exon 1 and the promoter region of the gene (7). The probe for the promoter region was prepared by PCR amplification of genomic DNA from a normocholesterolemic individual with oligonucleotide primers located in the intron adjacent to the 3' end of exon 1 and at bases −621 to −601 upstream from the AUG initiator codon (7). Probes were labeled with 32P by random primed synthesis (8).

Detection of point mutations by mismatch analysis

Twelve fragments of the LDL receptor gene comprising individual exons (exons 1, 2, 3, 4, 15, and 18) or pairs of exons with the intravening intron (exons 5 + 6, 7 + 8, 9 + 10, 11 + 12, 13 + 14, 16 + 17) were amplified by the polymerase chain reaction (PCR) (9) essentially as described previously (5) with oligonucleotide primers located in the adjacent introns (10); sequences containing a recognition site for the enzyme SalI were included at the 5' end of each oligonucleotide. The amplified fragment containing exon 1 also contained the adjacent 5' region of the gene, as described above.

Differences between the sequence of the amplified LDL receptor gene fragments from the proband and that from a normal control subject were detected by chemical cleavage of modified mismatched heteroduplexes, as described by Montandon and coworkers (11). The following modifications were used. The control DNA used as the probe was purified by agarose gel electrophoresis on 1.5% NuSieve gels (FMC BioProducts, Rockland, ME) before labeling. The fragment was recovered from the excised agarose by extraction with phenol (6) and labeled with 32P either by end-filling the SalI digested-fragment, which labels the 3’-end, or by incubation with T4 polynucleotide kinase, which labels the 5’-end (6). For the formation of heteroduplexes, 50–100 ng of labeled probe DNA was hybridized with a 5- to 10-fold excess of the unlabeled PCR product from the proband. To ensure that mismatches close to the ends of the fragments were detected, each amplified fragment from the proband was analyzed for mismatches with both a 3'-end-labeled probe and a 5'-end-labeled probe. PCR products from the proband were purified with Gene clean (Stratagene Ltd., UK) for mismatch analysis. To increase recovery of the final cleaved heteroduplexes, glycogen (20 µg) was added as carrier for the final ethanol precipitation.

The DNA sequence of PCR products was determined directly by the Sequenase method (USB, Cambridge BioScience, Cambridge, UK) with the modifications described by Casanova et al. (12) after purification of the DNA fragment by agarose gel electrophoresis as described above. Unless otherwise stated, primers for sequencing were the same as one of those used for PCR amplification of the fragment.

Detection of mutations by allele-specific oligonucleotide hybridization

Duplicate samples of amplified fragments of genomic DNA (usually 5 µl PCR reaction mix) were fractionated by agarose gel electrophoresis and transferred to duplicate nylon membranes (Biodyne A, Gallenkamp) by capillary blotting in 15 x SSC (6) for 1 h. The membranes were prehybridized for at least 30 min at 37°C in hybridization buffer (5 x SSPE, 5 x Denhardts, 0.5% w/v SDS (6)) and then one of the duplicate membranes hybridized with 1-5 x 10^5 cpm/ml of each of the pair of allele-specific 32P-labeled oligonucleotides for 1 h at 37°C. Oligonucleotides were end-labeled with gamma-32P-ATP by incubation with T4 polynucleotide kinase (6). After hybridization,
the membranes were washed three times for 10 min each at ambient temperature in 5 x SSPE, 0.1% w/v SDS and then for 20 min in the same buffer at the stringent wash temperature. The oligonucleotides for the detection of the gluo60 → lys mutation were 5'-GCTCAGAGCAAGGCG (normal) and 5'-GCTCAGAGCAAGGCG; the stringent wash temperature was 48°C. The oligonucleotides for the detection of the deletion in exon 15 were 5'-GTGGAGATGTGACAAT (normal) and 5'-GTGGAGATGTGACAAT; the stringent wash temperature was 42°C.

**Haplotype analysis**

The genotype of the LDL receptor gene was determined at four variable restriction enzyme sites, those for SfaN1 in exon 2 (13), AvaII in exon 15 (14), PvuII in intron 15 (15), and Ncol in exon 18 (16). The PvuII polymorphism was detected by Southern blotting described above, and the remainder was detected by PCR amplification of genomic DNA and restriction enzyme digestion or hybridization with allele specific oligonucleotides as described previously (5, 17).

**Cultured cells**

Skin fibroblasts from explants obtained by biopsy of the proband and his parents were maintained in culture as previously described (18). Total cytoplasmic RNA was isolated from fibroblasts that had been incubated for 12-16 h with medium containing lipoprotein-deficient serum (19) and fragments of the LDL receptor mRNA comprising exons 1-4 (500 bp), 12-15 (500 bp), and 15-18 (400 bp) of the gene were amplified by PCR with oligonucleotide primers located in the appropriate exons as described previously (20).

Methods for the immunoprecipitation of 32S-labeled LDL receptor protein from cultured cells have been described previously (21). For immunoblotting, cells were harvested and solubilized as described by van Driel and coworkers (22), and the proteins were separated and detected with specific monoclonal antibodies to the LDL receptor as described before (23).

**Site-directed mutagenesis and transient expression of LDL receptors in heterologous cells**

The gluo60 → Lys mutation was introduced into plasmid pLDLR4, a mammalian expression vector containing the human LDL receptor DNA under transcriptional control of the SV40 promoter (kindly provided by Dr. D. Russell, Dallas, Texas). A fragment of the LDL receptor cDNA, XbaI-EcoRI, was cloned into M13 mp18 and the mutation was introduced into single-stranded DNA by standard techniques (Amersham International, oligonucleotide directed in vitro mutagenesis system). Mutant M13 plaques were identified by hybridization with the mutant oligonucleotide under stringent conditions, and the presence of the mutation in the otherwise unchanged insert was confirmed by DNA sequencing. The mutant fragment was excised from the replicative form of the M13 and cloned into pLDLR4 using standard techniques (6). Stocks of monkey COS cells were maintained in culture in DMEM medium with high glucose (Gibco Europe Ltd.) supplemented with 10% v/v fetal calf serum, penicillin (100 μl/ml), and streptomycin (100 μg/ml). For transfection, cells were seeded on day 1 at 5.5 x 10⁵ cells/dish in 9 cm diameter dishes (Nunc Gibco Europe Ltd.) in the same medium. On day 2, cells were washed twice with serum-free medium and incubated in 9 ml serum-free medium for 30 min before transfection.

Cells were transfected with plasmid DNA (10 μg/dish) by the standard calcium phosphate method as described by Gorman (24) and then incubated for 48 h in DMEM containing high glucose, supplemented with 10% fetal calf serum, penicillin, and streptomycin to allow expression of LDL receptors. Cell extracts were analyzed by SDS-PAGE and immunoblotting with 125I-labeled anti-LDL-receptor antibody 10A2 as described above.

**RESULTS**

The members of the family of the proband with a raised plasma cholesterol or premature CHD are shown in Fig. 1. The details of the plasma lipid values in the proband and his immediate family are shown in Table 1.

Southern blotting of genomic DNA isolated from the proband, his parents, and his sister did not reveal any major abnormalities in the LDL receptor genes of the family. Fragments of the gene comprising single exons, exon 1 together with the promoter region, or pairs of exons were amplified by PCR with oligonucleotide primers located in the adjacent introns. With one exception, the size of the fragments obtained from the proband were as expected from the published structure of the gene (7). When exons 9 and 10 were amplified together as a single fragment, the size of the PCR product was 0.52 kb instead of the expected 1.3 kb. However, amplification of genomic DNA from 10 normal control individuals also produced a product of 0.52 kb. Restriction enzyme mapping, sequencing, and hybridization with specific probes confirmed that this fragment comprised exons 9 and 10 together with an intron of 0.09 kb rather than one of 0.9 kb as reported (7). Since we have never observed the presence of a larger intron of 0.9 kb in the amplified fragment comprising exons 9 and 10, it is possible that the size of this intron reported in the earlier paper was not correct.

The absence of any gross abnormalities in the LDL receptor genes of the proband suggested that both mutant alleles contained point mutations or minor rearrangements. To detect these minor differences in gene sequence, the amplified fragments of the LDL-receptor...
gene from the proband were subjected to chemical mismatch analysis with probe fragments derived from a normocholesterolemic subject. Extra bands that were not detected in either the untreated probe DNA or in a normal control sample were present in the amplified fragments of exon 3 and exon 15 (Fig. 2). In all other fragments, no extra bands were seen that were not due to known polymorphic sites present in exons.

Direct sequencing of the purified amplified fragments revealed that the proband was heterozygous for a single base substitution of A for G in exon 3 that changes the codon for amino acid residue 80 in the mature protein from GAG (glutamic acid) to AAG (lysine), and for a single base pair deletion of an A residue in the coding strand for exon 15. The deletion results in a frameshift that changes the codon for amino acid residue 743 in the mature protein from ATA (isoleucine) to ATG (methionine) and introduces a termination codon in the adjacent position (Fig. 3). Amplification and sequencing of fragments of genomic DNA from the parents and sibling of the proband showed that the father and sister were heterozygous for the mutation in exon 3, while exon 3 in the mother was normal, and that the mother was heterozygous for the single base pair deletion in exon 15, while exon 15 in the father and sister was normal.

Thus the proband, although apparently homozygous, is a compound heterozygote with two different mutant alleles for the LDL receptor gene. This was confirmed by haplotype analysis based on four informative restriction fragment length polymorphism (RFLP) sites in the four members of the family. As shown in Fig. 4a, the allele carrying the deletion in exon 15 is characterized by the absence of the cutting sites for SfaNI in exon 2, PvuII in intron 15, AvaII in exon 13, and Ncol in exon 18, while that carrying the mutation in exon 3 is characterized by the presence of the cutting sites for SfaNI, AvaII, and Ncol, and the absence of the cutting site for PvuII. The presence of both point mutations was readily detected by hybridization of the appropriate amplified fragment of genomic DNA with specific oligonucleotides under stringent conditions, as shown in Fig. 4b and c.

Extracts of cultured skin fibroblasts from the proband and his parents were electrophoresed on nonreduced polyacrylamide gels containing SDS, followed by immunoblotting with specific monoclonal antibodies to the LDL receptor. As shown in Fig. 5A, the LDL receptor

---

**Fig. 1.** Kindred B with familial hypercholesterolemia. The homozygous proband is indicated by an arrow. Those members of the family known to have an elevated plasma cholesterol concentration, consistent with a diagnosis of heterozygous FH, are indicated by half-shaded symbols. Individual I1-I9 inclusive are from County Tyrone in Northern Ireland and are known to have suffered from severe premature CHD. Individual I10, who died age 43 years after a myocardial infarction, and the paternal grandmother (I2) of the proband were from Lancashire, England. Individual I11 attends the lipid clinic in Manchester, but was excluded from the screening procedure because he is a maternal uncle of the proband (see text for details).

---

**TABLE 1. Details of subjects**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age</th>
<th>Chol</th>
<th>TG</th>
<th>LDL-Chol</th>
<th>HDL-Chol</th>
<th>Clinical Diagnosis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proband</td>
<td>2</td>
<td>26.8</td>
<td>2.23</td>
<td>24.6</td>
<td>1.2</td>
<td>Homozygous FH</td>
<td>Tendon and cutaneous xanthoma</td>
</tr>
<tr>
<td>Father</td>
<td>30</td>
<td>9.8</td>
<td>1.38</td>
<td>8.1</td>
<td>1.1</td>
<td>Heterozygous FH</td>
<td>Family history of CHD</td>
</tr>
<tr>
<td>Mother</td>
<td>33</td>
<td>11.2</td>
<td>1.80</td>
<td>8.3</td>
<td>2.1</td>
<td>Heterozygous FH</td>
<td>Family history of CHD</td>
</tr>
<tr>
<td>Sister</td>
<td>4</td>
<td>7.3</td>
<td>0.44</td>
<td>6.0</td>
<td>1.1</td>
<td>Heterozygous FH</td>
<td></td>
</tr>
</tbody>
</table>

*Calculated values (35).

*In the third trimester of pregnancy.

*Coronary heart disease (CHD).
Fig. 2. Mismatch analysis of amplified fragments of the LDL receptor gene from the proband. Heteroduplexes between a 32P end-labeled fragment of DNA amplified by PCR from the LDL receptor gene of a control subject (probe) and the equivalent unlabeled fragment from the proband (sample P) or control subject (sample C) were subjected to chemical modification with either hydroxylamine (Hy) or osmium tetroxide (Os) and cleavage as described in the text. The cleaved products were fractionated by electrophoresis on a 6% denaturing polyacrylamide gel; autoradiography was for 18 h at -70°C. The data are shown for fragments comprising exon 3 and exon 15, each hybridized with a 5'-end-labeled probe. The arrows on the left of the figure mark the positions of bands that were visible in the cleaved heteroduplexes between the sample from the proband and the probe that were not present in the labeled probe alone (lanes 1 and 8) or in the cleaved heteroduplexes between the control sample and the probe.

Fig. 3. DNA sequence of part of the amplified fragments comprising exon 3 and exon 15 of the LDL receptor gene in family R. The amplified PCR product comprising exon 3 and exon 15 from the proband was purified by agarose gel electrophoresis and the DNA sequence was determined as described in Methods. A: Exon 3. The amplification primer located at the 3' end of the fragment was used as the sequencing primer, so that the sequence shown is that of the noncoding strand. The proband is heterozygous (htz) for a point mutation of C to T in the codon for residue 80 (G to A in the coding strand). B: Exon 15. The amplification primer located at the 5' end of the fragment was used as the sequencing primer, so the sequence shown is that of the coding strand. The sequence in the proband is compatible with a heterozygous (htz) deletion of a single A residue from the codon for amino acid residue 743, causing a frameshift and introducing a new stop codon in the adjacent residue.
revealed a band of LDL receptor protein that was similar in size to the endogenous COS cell receptor. When the LDL receptor cDNA with the glu<sub>80</sub> → lys mutation was expressed, a band corresponding to the slowly migrating form of the mature protein found in cultured skin fibroblasts from the proband was detected in addition to the minor band of endogenous COS cell LDL receptor (Fig. 6). The proportion of the expressed glu<sub>80</sub> → lys mutant receptor that was present as a high molecular weight form of the protein was greater than that of the normal protein.

Total cytoplasmic RNA was isolated from cultured skin fibroblasts of the proband and his parents and fragments of the LDL receptor mRNA were amplified by PCR. Direct sequencing of the fragment encompassing the deleted base in exon 15 from the proband and mother revealed the presence of the normal sequence only, suggesting that the mRNA derived from the defective maternal allele was present at low concentration in both individuals. When the amplified fragment containing the polymorphic AvaII site in exon 13 was digested with AvaII (Fig. 7A), the majority of the fragment from the proband's mRNA was cleaved, suggesting that it was derived mainly from the allele inherited from his father (AvaII+) and not from the allele inherited from his mother (AvaII−). By comparison with results obtained when mixtures of different proportions of the fragments from the parents were analyzed, it was estimated that the mRNA derived from the maternal allele comprised approximately 10% of the total LDL receptor mRNA in the cells from the proband (Fig. 7B). Part of an amplified genomic fragment containing the promoter region, comprising approximately 250 base pairs upstream from exon 1, was also sequenced for each member of the family and found to be identical with the normal sequence (data not shown).

Genomic DNA from two groups of apparently unrelated FH patients attending lipid clinics either in London
Two new point mutations in the LDL receptor gene have been detected in a homozygous FH patient of English origin. The technique for mismatch analysis to detect point mutations was essentially that described by Montandon and coworkers (11), but an essential modification was included for the analysis of larger DNA fragments, in that the mismatch was carried out twice, once with the probe DNA labeled at the 3' end and once with a probe labeled at the 5' end. In this way it was ensured that mismatches close to one and of a fragment would be readily detected by the presence of small cleavage products, as well as by large cleavage products that did not separate well from the excess labeled probe DNA.

The mutant allele inherited by the proband from his mother has a single base pair deletion that introduces a new termination codon in the O-linked sugars domain of the LDL receptor, but no truncated protein could be detected in cultured skin fibroblasts from the proband or his (200 patients) or in Manchester (77 patients), was analyzed by gene amplification and hybridization with allele-specific oligonucleotides. The presence of the mutation in samples that gave a positive signal with either of the mutant oligonucleotides was confirmed by DNA sequencing. In the London sample, five individuals were found to carry the glu80 → lys mutation; in three of these the haplotype of the mutant allele based on four RFLPs was determined unambiguously by comparing DNA from the patient with that of affected and unaffected relatives, and was found to be the same as that in the proband and his father (Table 2). In the Manchester sample, eleven unrelated individuals were found with the glu80 → lys mutation but relatives of the majority of these patients were not available for haplotype analysis.

The single base pair deletion in exon 15 found in the proband and his mother was not detected in any unrelated patients in the Manchester sample, or any patients in the London sample.

DISCUSSION

Two new point mutations in the LDL receptor gene have been detected in a homozygous FH patient of English origin. The technique for mismatch analysis to detect point mutations was essentially that described by Montandon and coworkers (11), but an essential modification was included for the analysis of larger DNA fragments, in that the mismatch was carried out twice, once with the probe DNA labeled at the 3' end and once with a probe labeled at the 5' end. In this way it was ensured that mismatches close to one and of a fragment would be readily detected by the presence of small cleavage products, as well as by large cleavage products that did not separate well from the excess labeled probe DNA.

The mutant allele inherited by the proband from his mother has a single base pair deletion that introduces a new termination codon in the O-linked sugars domain of the LDL receptor, but no truncated protein could be detected in cultured skin fibroblasts from the proband or his
of the antibodies used for immunoblotting was anti-
mother with specific antibody to the LDL receptor. One
antigenic site in the first disulfide-rich repeat in the binding
domain of the protein and should be able to detect a puta-
tive truncated receptor with the first three domains intact (27).

In cells with the Lebanese allele of the LDL receptor
gene, in which a point mutation introduces a stop codon
in exon 14, a truncated protein is synthesized but is present
in cells at a very low level (28). However, two other mutant alleles into which a stop codon has been introduced by a frameshift, caused either by an insertion in exon 8 (2) or by a 4 kb deletion between exons 12 and 15 (29), produce no detectable LDL receptor protein. Cultured cells from the proband contained only a small amount of mRNA derived from this allele, suggesting that the mRNA is unstable in the cells. There was no evidence for any mutation in the putative promoter region that would affect the rate of transcription, but we cannot rule out the existence of an additional mutation in some cis-
acting regulatory element in the flanking regions of the gene at a more distant locus. Premature termination codons introduced by mutation into the β-globin gene are known to destabilize the mRNA in some cases (30), and cells carrying either of the two alleles described above in which stop codons have been introduced also appear to contain less mRNA than normal (31).

The mutant allele inherited by the proband and his sibling from their father has a single base change that would be expected to cause the glutamic acid residue at position 80 in the mature protein to be substituted with lysine. This residue occurs in the second disulfide-rich repeat in the binding domain of the receptor protein, and affects processing and intracellular transport of the newly synthesized protein. It also results in a mature protein that migrates abnormally slowly on nonreduced gels, although the protein migrates normally when fully reduced. A similar phenotype was observed when a plasmid containing an LDL receptor cDNA with the mutation was expressed in COS cells. The normal LDL receptor

### TABLE 2. Genotype of the LDL receptor gene in FH patients with the glu80 → lys mutation

<table>
<thead>
<tr>
<th>Patient</th>
<th>Ethnic Origin</th>
<th>Glu80 → Lys</th>
<th>Haplotypes/Genotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proband hnz*</td>
<td>UK (Manchester)</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
<tr>
<td>London 1 hnz</td>
<td>English</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
<tr>
<td>2 hnz</td>
<td>English</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
<tr>
<td>3 hnz</td>
<td>English</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
<tr>
<td>4 hnz</td>
<td>Irish</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
<tr>
<td>5 hnz</td>
<td>English</td>
<td>+ -</td>
<td>S+ A+ P- N+</td>
</tr>
</tbody>
</table>

*5'SflN I, A (Avail), P (PvuII), and N (Ncol) denote variable restriction enzyme sites in the LDL receptor gene; + indicates the presence and - the absence of the site. Where the haplotype of the mutant allele could not be determined unambiguously, the genotype at that site is given.

*The patient has a clinical diagnosis of homozygous (hnz) or heterozygous (hzt) familial hypercholesterolemia.

*This patient is a compound heterozygote; the second mutant allele has a large deletion at the 5' end of the gene (X-M. Sun and A. K. Soutar, unpublished observations).
protein isolated from cultured cells is partially dimerized (22), and we observed that the mutant receptor was more susceptible to dimerization to a higher molecular weight form, especially when expressed in heterologous cells. These data suggest that the normal formation of disulfide bonds in the second repeat may be impeded in this mutant protein.

The glu80 to lys mutation was also found in five unrelated individuals in a sample of 200 patients with a clinical diagnosis of FH who were attending lipid clinics in the London area. Haplotype analysis of the mutant alleles was possible in some cases and showed that it was likely that all the patients had inherited the same mutant allele, although the observed haplotype, based on four RFLP sites in the gene, is relatively common in this population (32, 33). The data of Leitersdorf, Chakravarti, and Hobbs (32) suggest that little additional information would be gained by analysis of the other common polymorphic sites in the LDL receptor gene, for example those for ApaI or SphI, because of linkage disequilibrium with the RFLP sites already analyzed. Two of the patients with the glu80 to lys mutation were originally from the northwest of England, one from the Midlands, one from the southeast, and the other a first generation immigrant from Ireland. Perhaps more striking was the frequency of this mutation in the FH patients attending a lipid clinic in Manchester, where it was found in 11 out of 77 unrelated patients. It was not possible to determine the haplotype of the mutant allele in these patients, but their genotype at the LDL receptor locus was compatible with them all having inherited the same mutant allele. Since the family of the proband's father are from Lancashire, it is proposed that the glu80 to lys mutation should be named FH Lancashire according to the nomenclature of Hobbs and coworkers (2). The frequency of this mutation in English FH patients and its presence in Irish patients suggests that it might also be found in individuals of English or Irish origin in the United States.

In marked contrast, the mutation in the gene inherited by the proband from his mother was not detected in any unrelated patients in the Manchester sample or in any individuals in the London sample. The DNA sequence in which the deletion occurs is CACCACGGTGGAGATGTGACAAATTG, where the deleted base is indicated by the lower case letter, which contains several elements associated with the frequent occurrence of deletions in other genes (34). In particular, it contains a sequence identical to a consensus sequence (underlined in the sequence above) derived from sequences in other genes that have been identified as 'deletion hot spots', where multiple small deletions have occurred at the same sites in the human genome (34). The family of the proband's mother is of Northern Irish origin, and we propose that this mutation should be named FH Tyrone according to the nomenclature of Hobbs and coworkers (2). It will be of interest to determine whether this mutation also occurs in other FH patients in Ireland or in Irish-Americans in the United States; it does not appear to be widespread in the two populations described in this study, unlike the mutation present in exon 3.

The authors are indebted to Dr. T. Brocklebank (consultant pediatrician) and Dr. M. Henderson (chemical pathologist) at St. James' Infirmary, Leeds, for samples and information about the proband and his family. Blood samples from FH patients attending lipid clinics in London were kindly provided by Dr. G. R. Thompson (Hammersmith Hospital) and Dr. M. Seed (Charing Cross Hospital). We are grateful to Professor S. Humphries and L. King-Underwood (Charing Cross Sunley Research Centre) for providing DNA from some of these samples. Blood samples from FH patients attending the lipid clinics in Manchester were supplied by Dr. P. Durrington (Manchester Royal Infirmary) and Dr. P. Miller (Withington Hospital). We are grateful to Dr. P. Talmud (Charing Cross Sunley Research Centre) for providing DNA from these samples and to Dr. D. Batnagar (Manchester Royal Infirmary) for information about some of the proband's family. Plasmids pLDR3 and pLDR4 were kind gifts from Dr. D. Russell, Dallas, Texas. We are grateful to Mrs. E. Manson for secretarial help. This work was supported by the Medical Research Council and by the British Heart Foundation (Grant no. 1891047). Dr. Xi-Ming Sun is sponsored by the British Council.

Manuscript received 19 September 1991 and in revised form 17 January 1992.

REFERENCES


